Komori
Other Disclosures2784Alfresa Holdings CorporationTrading & Wholesale

Participation in the ASAGI Labs Longevity Consortium to Study Research and Social Implementation in the Longevity Field

アルフレッサ ホールディングス joined the Longevity Consortium established by ASAGI Labs, a general incorporated foundation. It will consider research and development, joint projects, and social implementation with other participants relating to extending healthy life expectancy and sustainable social participation.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

ASAGI Labs Longevity Consortium
Applicable field (uses covered by this announcement)

Extending healthy life expectancy, sustainable social participation, healthcare, food, housing, beauty, maternal and child health and development, health management for people in their 20s and 30s, career development, extending healthy life expectancy throughout life, AI technology, and life planning

Launch dateFull-scale activities commence on 1 June 2026.
Relationship between the counterparty and the company
Alfresa Holdings Corporation2784
Relationship with the Company

The company is a participating member of the consortium. Its capital and personnel relationships are not disclosed.

Counterparty一般財団法人ASAGI Labs, 株式会社ASAGI Labs, アサヒクオリティーアンドイノベーションズ株式会社, NTTプレシジョンメディシン株式会社, Meiji Holdings Co.,Ltd., Morinaga & Co.,Ltd., ROHTO PHARMACEUTICAL CO.,LTD., National University of Singapore

一般財団法人ASAGI Labs (Representative Director: Hayano Motoshi (早野元詞)). ASAGI Labs seeks to create innovation in fields related to daily life, including healthcare, food, housing, and beauty. The locations, representatives, capital, year of establishment, and business activities of the other counterparties are not disclosed.

Impact on Business Performance

The impact of this matter on results for the current fiscal year is minor.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Ministry of Health, Labour and Welfare, “Toward a 100-Year Life”

Announced details
ItemDetails
Names of Products / Services CoveredASAGI Labs Longevity Consortium
Counterparty一般財団法人ASAGI Labs, 株式会社ASAGI Labs, アサヒクオリティーアンドイノベーションズ株式会社, NTTプレシジョンメディシン株式会社, Meiji Holdings Co.,Ltd., Morinaga & Co.,Ltd., ROHTO PHARMACEUTICAL CO.,LTD., National University of Singapore
Counterparty overview一般財団法人ASAGI Labs (Representative Director: Hayano Motoshi (早野元詞)). ASAGI Labs seeks to create innovation in fields related to daily life, including healthcare, food, housing, and beauty. The locations, representatives, capital, year of establishment, and business activities of the other counterparties are not disclosed.
Relationship with the CompanyThe company is a participating member of the consortium. Its capital and personnel relationships are not disclosed.
Launch dateFull-scale activities commence on 1 June 2026.
Applicable areaExtending healthy life expectancy, sustainable social participation, healthcare, food, housing, beauty, maternal and child health and development, health management for people in their 20s and 30s, career development, extending healthy life expectancy throughout life, AI technology, and life planning
Impact on Business PerformanceThe impact of this matter on results for the current fiscal year is minor.
SourceMinistry of Health, Labour and Welfare, “Toward a 100-Year Life”
Items this document does not state (10)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To contribute to extending healthy life expectancy and resolving social issues through industry-government-academia-finance collaboration, drawing on the expertise it has developed in the medical and healthcare fields.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Participation in the ASAGI Labs Longevity Consortium to Study Research and Social Implementation in the Longevity Field | Alfresa Holdings Corporation (2784) timely disclosure | Komori